Skip to main content

Table 1 Patient characteristics (n = 50)

From: Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Characteristics Data
Age, years, median (range) 58 (34–79)
Race
 White 47 (94%)
 Black 3 (6%)
Menopausal status
 Premenopausal 18 (36%)
 Postmenopausal 32 (64%)
PgR
 Negative 3 (6%)
 Positive 47 (94%)
Tumor grade
 1 12 (24%)
 2 31 (62%)
 3 7 (14%)
Clinical stage
 II 36 (72%)
 III 14 (28%)
  1. PgR - Progesterone